Abstract
Diffuse large B-cell lymphoma(DLBCL) is a common aggressive non-Hodgkin lymphoma(NHL). When rituximab combined with cyclophosphamide, doxorubicin, vincristine, and methylprednisolone chemotherapy regimen is applied, the cure rate of DLBCL patients can reach 60%-80%. However, DLBCL possesses prominent heterogeneity of molecular pathology, and different patients have different efficacies and prognoses. Therefore, the correct evaluation of efficacy and prognosis is the focus of the current study. 18F-FDG PET/CT is an imaging tool commonly used for DLBCL patients during therapeutic and prognostic evaluation. The international prognostic index(IPI) and the national comprehensive cancer network-international prognostic index (NCCN-IPI) are widely used clinical prognostic scoring systems for malignant lymphoma. Recently, the prognostic value of a number of new clinical and molecular pathological factors has been explored. This study reviews the application, research progress, and development trend of PET/CT, clinical prognostic score system, different clinical and molecular pathologic prognostic factors during treatment evaluation, and prognosis of DLBCL patients. Key words: Lymphoma; B-cell; Positron-emission tomography; Tomography, X-ray computed; Standardized uptake value; Response assement; Prognosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
